Abstract: A system can include one or more processors; memory; a data interface that receives data; a control interface that transmits control signals for control of pumps of a hydraulic fracturing operation; and one or more components that can include one or more of a modeling component that predicts pressure in a well fluidly coupled to at least one of the pumps, a pumping rate adjustment component that generates a pumping rate control signal for transmission via the control interface, a capacity component that estimates a real-time pumping capacity for each individual pump, and a control component that, for a target pumping rate for the pumps during the hydraulic fracturing operation, generates at least one of engine throttle and transmission gear settings for each of the individual pumps using an estimated real-time pumping capacity for each individual pump where the settings are transmissible via the control interface.

Abstract: Systems and methods for tracking, collecting, processing, enriching, analyzing and reporting on data in the context of cyber security investigations are disclosed. According to one embodiment, in an information processing apparatus comprising at least one computer processor, a method for conducing cyber investigations may include: (1) receiving initiation of an investigative workflow comprising contextual information including at least one of a case, a data asset, a subject, and a threat; (2) collecting digital evidence from the data asset; (3) processing the digital evidence into structured data; (4) staging and enriching the structured data; (5) analyzing the enriched structured data; and (6) generating at least one report based on the analysis.

Abstract: In certain embodiments the invention is directed to a single layer controlled release pharmaceutical formulation comprising a tablet consisting of a single layer matrix comprising a therapeutically effective amount of alfuzosin or a pharmaceutically acceptable salt thereof dispersed in a controlled release material, wherein the formulation following single dose administration under fed conditions exhibits a mean time to maximum plasma concentration of about 3 hours to about 14 hours.

Abstract: In certain embodiments the invention is directed to an oral solid pharmaceutical dosage form comprising: a first portion of a short acting sedative-hypnotic in an release immediate release component; and a second portion of the sedative-hypnotic in a delayed component, the delayed release component comprising (i) a unitary core comprising the second portion of sedative-hypnotic dispersed in a controlled release matrix and (ii) a delayed release coating surrounding the core.

Abstract: A controlled release pharmaceutical dosage form comprising bupropion or pharmaceutically acceptable salt thereof.

Abstract: A controlled release pharmaceutical formulation for the administration of an antihistamine and decongestant to a patient wherein the formulation employs a compressed matrix core for the controlled release of a decongestant and an immediate release coating for the immediate release of the antihistamine.

Abstract: A pharmaceutical composition of omeprazole for oral administration is described which consists essentially of: (a) a pellet comprising an inert core component, a therapeutically effective amount of omeprazole, a surface active agent, a filler, a pharmaceutically acceptable alkaline agent and a binder; and (b) a single layer of coating on said pellet which comprises a layer of an enteric coating agent.

Abstract: A pharmaceutical composition of omeprazole for oral administration is described which consists essentially of:

Abstract: A controlled release pharmaceutical formulation for the administration of an antihistamine and decongestant to a patient wherein the formulation employs a compressed matrix core for the controlled release of a decongestant and an immediate release coating for the immediate release of the antihistamine.

Abstract: A controlled release dosage form for an analgesic that does not contain an expanding polymer and comprising a core containing the analgesic, preferably tramadol or it pharmaceutically acceptable deviates and a semipermeable membrane coating the core.

Abstract: A pharmaceutical composition of omeprazole for oral administration is described which consists essentially of:(a) a pellet comprising an inert core component, a therapeutically effective amount of omeprazole, a surface active agent, a filler, a pharmaceutically acceptable alkaline agent and a binder; and(b) a single layer of coating on said pellet which comprises a layer of an enteric coating agent.

Abstract: A pharmaceutical composition of omeprazole for oral administration is described which consists essentially of:(a) a pellet comprising an inert core component, a therapeutically effective amount of omeprazole, a surface active agent, a filler, a pharmaceutically acceptable alkaline agent and a binder; and(b) a single layer of coating on said pellet which comprises a layer of an enteric coating agent.